Oncternal Therapeutics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Oncternal Therapeutics's earnings have been declining at an average annual rate of -11.3%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 14.2% per year.
Belangrijke informatie
-11.3%
Groei van de winst
53.7%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.0% |
| Inkomstengroei | -14.2% |
| Rendement op eigen vermogen | -228.3% |
| Nettomarge | -1,948.7% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation
Jun 14
Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?
Mar 03Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Nov 06Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely
Jul 12We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Jan 12FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy
Oct 03Oncternal Therapeutics begins phase 3 study of zilovertamab
Sep 27Oncternal Therapeutics: Selling For Under Cash Value
Sep 02Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M
Aug 09Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Aug 07Oncternal to collaborate with an AbbVie company for its phase 3 lymphoma study
Jul 14Oncternal Therapeutics: As Phase 2 Study Matures, Data Continues To Improve
Jun 07We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Apr 12Oncternal Therapeutics: Trading Near Cash With Impressive Results
Jan 04Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans
Nov 09Oncternal Therapeutics: Keep An Eye On This Biopharmaceutical Company
Oct 10Oncternal: Solid Data In 2 Cancers With High Unmet Need
Jun 17We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth
May 05Should Oncternal Therapeutics (NASDAQ:ONCT) Be Disappointed With Their 81% Profit?
Mar 01Opbrengsten en kosten
Hoe Oncternal Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 2 | -36 | 13 | -1 |
| 31 Mar 24 | 1 | -36 | 13 | 0 |
| 31 Dec 23 | 1 | -39 | 13 | 0 |
| 30 Sep 23 | 1 | -42 | 13 | 2 |
| 30 Jun 23 | 1 | -43 | 13 | 2 |
| 31 Mar 23 | 1 | -46 | 13 | 0 |
| 31 Dec 22 | 1 | -44 | 13 | 0 |
| 30 Sep 22 | 2 | -41 | 13 | 0 |
| 30 Jun 22 | 4 | -39 | 12 | 0 |
| 31 Mar 22 | 4 | -35 | 12 | 0 |
| 31 Dec 21 | 4 | -31 | 12 | 0 |
| 30 Sep 21 | 5 | -26 | 10 | 0 |
| 30 Jun 21 | 4 | -21 | 10 | 0 |
| 31 Mar 21 | 4 | -18 | 9 | 0 |
| 31 Dec 20 | 3 | -17 | 8 | 0 |
| 30 Sep 20 | 3 | -19 | 9 | 0 |
| 30 Jun 20 | 2 | -19 | 10 | 0 |
| 31 Mar 20 | 3 | -37 | 9 | 0 |
| 31 Dec 19 | 2 | -34 | 7 | 0 |
| 30 Sep 19 | 2 | -31 | 5 | 0 |
| 30 Jun 19 | 2 | -28 | 3 | 0 |
| 31 Mar 19 | 3 | -7 | 2 | 0 |
| 31 Dec 18 | 3 | -7 | 2 | 0 |
| 31 Dec 17 | 2 | -10 | 3 | 0 |
Kwaliteitswinsten: ONCT is currently unprofitable.
Groeiende winstmarge: ONCT is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: ONCT is unprofitable, and losses have increased over the past 5 years at a rate of 11.3% per year.
Versnelling van de groei: Unable to compare ONCT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: ONCT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: ONCT has a negative Return on Equity (-228.34%), as it is currently unprofitable.